Literature DB >> 11171708

The costs of treating COPD in the United States.

S A Strassels1, D H Smith, S D Sullivan, P S Mahajan.   

Abstract

STUDY
OBJECTIVES: COPD affects millions of people in the United States. The purpose of this study was to describe the medical resource use and costs incurred by persons with COPD in the United States in 1987.
DESIGN: Data for this study were derived from the 1987 National Medical Expenditure Survey. A societal perspective was adopted for this analysis. PATIENTS OR PARTICIPANTS: All persons > or = 40 years old with resource use or expenditures for chronic bronchitis, emphysema, or nonspecific chronic airway obstruction were included in this study.
RESULTS: Mean per-person direct medical expenditures among persons with COPD were $6,469 (1987 US dollars), about 25% of which was COPD related. Approximately 68% of direct medical expenditures in persons with COPD were for inpatient hospitalization.
CONCLUSIONS: COPD causes a large societal burden of illness that is expected to increase. This study provides a valuable foundation and historical measure against which to compare other estimates.

Entities:  

Mesh:

Year:  2001        PMID: 11171708     DOI: 10.1378/chest.119.2.344

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  62 in total

1.  Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study.

Authors:  Ken M Kunisaki; Dennis E Niewoehner; John E Connett
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

Review 2.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

Review 3.  Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; M Rutten-Van Mölken; J Buffels; O Van Schayck; P-A Gevenois; R Pellegrino; E Derom; W De Backer
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

Review 4.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Effectiveness of Umeclidinium-Vilanterol for Protocolized Management of Chronic Obstructive Pulmonary Disease Exacerbation in Hospitalized Patients: A Sequential Period Analysis.

Authors:  Todd W Chapin; Michael A Mann; Gary L Brown; Traci L Leitheiser; Becky Anderson; David D Leedahl
Journal:  Chronic Obstr Pulm Dis       Date:  2018-01-24

6.  Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).

Authors:  Mitchell Friedman; Shailendra S Menjoge; Susan F Anton; Steven Kesten
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 7.  The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.

Authors:  Barbara P Yawn; Ibrahim Raphiou; Judith S Hurley; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-06-03

8.  Effectiveness and cost-effectiveness of early assisted discharge for chronic obstructive pulmonary disease exacerbations: the design of a randomised controlled trial.

Authors:  Cecile M A Utens; Lucas M A Goossens; Frank W J M Smeenk; Onno C P van Schayck; Walter van Litsenburg; Annet Janssen; Monique van Vliet; Wiel Seezink; Dirk R A J Demunck; Brigitte van de Pas; Peter J de Bruijn; Anouschka van der Pouw; Jeroen M A M Retera; Petra de Laat-Bierings; Loes van Eijsden; Maria Braken; Riet Eijsermans; Maureen P M H Rutten-van Mölken
Journal:  BMC Public Health       Date:  2010-10-18       Impact factor: 3.295

Review 9.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Authors:  Christopher M Blanchette; Nicholas J Gross; Pablo Altman
Journal:  Am Health Drug Benefits       Date:  2014-04

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.